Otsuka's Samsca approved in EU
This article was originally published in Scrip
Executive Summary
The European Commission has approved Otsuka's Samsca (tolvaptan) for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH), making it the first oral vasopressin receptor antagonist to be approved in Europe.